

# **The effect of treatment on the microbiota of patients diagnosed with colonic lesions**

Marc A Sze<sup>1</sup>, Nielson T Baxter<sup>2</sup>, Mack T Ruffin IV<sup>3</sup>, Mary AM Rogers<sup>2</sup>, and Patrick D Schloss<sup>1†</sup>

† To whom correspondence should be addressed: [pschloss@umich.edu](mailto:pschloss@umich.edu)

<sup>1</sup> Department of Microbiology and Immunology, University of Michigan, Ann Arbor, MI

<sup>2</sup> Department of Internal Medicine, University of Michigan, Ann Arbor, MI

<sup>3</sup> Department of Family Medicine and Community Medicine, Penn State Hershey Medical Center, Hershey, PA

## Abstract

**Background.** Colorectal cancer (CRC) is a worldwide health problem. Despite growing evidence that members of the gut microbiota can drive tumorigenesis, little is known about what happens to the microbiota after treatment for an adenoma or carcinoma. This study tested the hypothesis that treatment for adenoma or carcinoma alters the abundance of bacterial populations associated with disease to those associated with a normal colon. We tested this hypothesis by sequencing the 16S rRNA genes in the feces of 67 individuals before and after treatment for adenoma (N=22), advanced adenoma (N=19), and carcinoma (N=26).

**Results.** There were large changes to the bacterial communities associated with treatment across the three groups. The communities from patients with carcinomas changed significantly more than those with adenoma following treatment (P-value < 0.001). There was no significant change in the microbiota between patients with adenoma and advanced adenoma, or between patients with advanced adenoma and carcinoma (P-value > 0.05). Although treatment was associated with intrapersonal changes, the change in the abundance of individual OTUs to treatment was not consistent within diagnosis groups (P-value > 0.05). Because the distribution of OTUs across patients and diagnosis groups was irregular, we used the Random Forest machine learning algorithm to identify groups of OTUs that allowed us to successfully distinguish between pre and post-treatment samples for each of the diagnosis groups. Although the three models successfully differentiated between the pre and post-treatment samples, there was little overlap between the OTUs that were indicative of treatment. Next, we used a larger cohort that contained individuals with normal colons and those with adenomas, advanced adenomas, and carcinomas to determine whether individuals who underwent treatment were more likely to have OTUs associated with normal colons. We again built Random Forest models and measured the change in the positive probability of having one of the

three diagnoses. Only patients who had carcinomas experienced a significant decrease in positive probability of having a lesion after treatment ( $P\text{-value} < 0.05$ ), indicating that the microbial milieu of the colon more closely resembled that of a normal colon. Finally, we tested whether the type of treatment impacted the microbiota of those diagnosed with carcinomas and were unable to detect any significant differences in characteristics of these communities between individuals treated with surgery alone and those treated with chemotherapy or chemotherapy and radiation ( $P\text{-value} > 0.05$ ).

**Conclusions.** Further exploration of the relationship between diagnosis, treatment, and the impact on the microbiota will yield improvements in disease management.

## **Keywords**

microbiota; colorectal cancer; polyps; treatment; risk factor.

## Background

Colorectal cancer (CRC) is the third most common cause of cancer deaths in the United States [1,2]. Disease mortality has significantly decreased, predominately due to improvements in screening [2]. Despite these improvements, there are still approximately 50,000 CRC-related deaths per year in the United States [1]. Current estimates indicate that 20-30% of those who undergo treatment will experience recurrence and 35% of all patients will die within five years [3–5]. Identification of methods to assess patients' risk of recurrence is of great importance to reduce mortality and healthcare costs.

There is growing evidence that the gut microbiota is involved in the progression of CRC. Mouse-based studies have identified populations of *Bacteroides fragilis*, *Escherichia coli*, and *Fusobacterium nucleatum* that alter disease progression [6–10]. Furthermore, studies that shift the structure of the microbiota through the use of antibiotics or inoculation of germ free mice with human feces have shown that varying community compositions can result in varied tumor burden [11–13]. Collectively, these studies support the hypothesis that the microbiota can alter the amount of inflammation in the colon and with it the rate of tumorigenesis [14].

Building upon this evidence, several human studies have identified unique signatures of colonic lesions [15–20]. One line of research has identified community-level differences between those bacteria that are found on and adjacent to colonic lesions and have supported a role for *Bacteroides fragilis*, *Escherichia coli*, and *Fusobacterium nucleatum* in tumorigenesis [21–23]. Others have proposed feces-based biomarkers that could be used to diagnose the presence of colonic adenomas and carcinomas [24–26]. These studies have associated *Fusobacterium nucleatum* and other oral pathogens with colonic lesions (adenoma, advanced adenoma, and carcinoma). They have also noted that the loss of bacteria generally thought to produce short chain fatty acids, which can suppress

inflammation, is associated with colonic lesions. This suggests that gut bacteria have a role in tumorigenesis with potential as useful biomarkers for aiding in the early detection of disease.

Despite advances in understanding the role between the gut microbiota and colonic tumorigenesis, we still do not understand how treatments including resection, chemotherapy, and/or radiation affect the composition of the gut microbiota. If the community drives tumorigenesis then one would hypothesize that treatment to remove a lesion would affect the microbiota and risk of recurrence. To test this hypothesis, we addressed two related questions: Does treatment affect the colonic microbiota in a predictable manner? If so, does the treatment alter the community to more closely resemble that of individuals with normal colons?

We answered these questions by sequencing the V4 region of 16S rRNA genes amplified from fecal samples of individuals with adenoma, advanced adenoma, and carcinomas pre and post-treatment. We used classical community analysis to compare the alpha and beta-diversity of communities pre and post treatment. Next, we generated Random Forest models to identify bacterial populations that were indicative of treatment for each diagnosis group. Finally, we measured the predictive probabilities to assess whether treatment yielded bacterial communities similar to those individuals with normal colons. We found that treatment alters the composition of the gut microbiota and that, for those with carcinomas, the gut microbiota shifted more towards that of a normal colon after treatment. In the individuals with carcinomas, no difference was found by the type of treatment (surgery alone versus surgery with chemotherapy). Understanding how the community responds to these treatments could be a valuable tool for identifying biomarkers to quantify the risk of recurrence and the likelihood of survival.

## Results

### ***Treatment alters the bacterial community structure of patients diagnosed with***

***colonic lesions.*** Within our 67-person cohort we tested whether the microbiota of patients with adenoma (N=22), advanced adenoma (N=19), or carcinoma (N=26) had any broad differences between pre and post-treatment samples [Table 1]. The structure of the microbial communities of the pre and post-treatment samples differed, as measured by the  $\theta_{YC}$  beta diversity metric [Figure 1A]. We found that the communities obtained pre and post-treatment among the patients with carcinomas changed significantly more than those patients with adenoma (P-value = 5.4e-05). There were no significant differences in the amount of change observed between the patients with adenoma and advanced adenoma or between the patients with advanced adenoma and carcinoma (P-value > 0.05). Next, we tested whether there was a consistent direction in the change in the community structure between the pre and post-treatment samples for each of the diagnosis groups [Figure 1B-D]. We only observed a consistent shift in community structure for the patients with carcinoma when using a PERMANOVA test (adenoma P-value=0.999, advanced adenoma P-value=0.945, and carcinoma P-value=0.005). Finally, we measured the number of observed OTUs, Shannon evenness, and Shannon diversity in the pre and post-treatment samples and did not observe a significant change for any of the diagnosis groups (P-value > 0.05) [Table S1].

### ***The effects of treatment are not consistent across treatment groups.***

We used two approaches to identify those bacterial populations that change between the two samples for each diagnosis group. First, we sought to identify individual OTUs that could account for the change in overall community structure. However, using a paired Wilcoxon test we were unable to identify any OTUs that were significantly different in the pre and post-treatment groups [Figure S1]. It is likely that high inter-individual variation and the irregular distribution of OTUs across individuals limited the statistical power of the test. To overcome these

problems we developed Random Forest models to identify collections of OTUs that would allow us to differentiate between pre and post-treatment samples from each of the diagnosis groups. Because of the relatively small number of subjects in each group, we restricted our models to only incorporate 10 OTUs to limit the likelihood that the models would overfit the data. Despite this restriction, the models performed well (adenoma AUC range =0.69 - 0.92, advanced adenoma AUC range =0.80 - 1.00, carcinoma AUC range =0.82 - 0.98). Interestingly, the 10 OTUs that were used for each model had little overlap with each other [Figure 2]. These results support the earlier community-wide analysis where we observed that the treatment had an impact on the overall community structure; however, the effect of treatment was not consistent across patients and diagnosis groups.

***Post-treatment samples from patients with carcinoma more closely resemble those of a normal colon.***

Next, we determined whether treatment changed the microbiota in a way that the post-treatment communities resembled that of patients with normal colons. To test this, we used an expanded cohort of 423 individuals that were diagnosed under the same protocol as having normal colons or colons with adenoma, advanced adenoma, or carcinoma [Table 2]. We then constructed Random Forest models to classify the study samples, with the 3 diagnosis groups (adenoma, advanced adenoma, or carcinoma), or having a normal colon. The models performed well (adenoma AUC range =0.62 - 0.72, advanced adenoma AUC range=0.68 - 0.77, carcinoma AUC range=0.84 - 0.90; Figure S2). The OTUs that were incorporated into the adenoma and advanced adenoma models largely overlapped and those OTUs that were used to classify the carcinoma samples were largely distinct from those of the other two models [Figure 3A]. Among the OTUs that were shared across the three models were those populations generally considered beneficial to their host (e.g. *Faecalibacterium*, *Lachnospiraceae*, *Bacteroides*, *Dorea*, *Anaerostipes*, and *Roseburia*) [Figures 3B]. Although many of these OTUs were also included in the model differentiating between patients with normal colons and those with carcinoma, this model also included OTUs affiliated with populations that have previously been associated

with carcinoma (*Fusobacterium*, *Porphyromonas*, *Parvimonas*) [24–26] [Figure S3]. Finally, we applied these three models to the pre and post-treatment samples for each diagnosis group and quantified the change in the positive probability of the model. A decrease in the positive probability would indicate that the colon more closely resembled that of a patient with a normal colon. There was no significant change in the positive probability for the adenoma or advanced adenoma groups [Figure 4]. The positive probability for the pre and post-treatment samples from patients diagnosed with carcinoma significantly decreased with treatment. Only, 6 of the 26 patients (23.08%) who were diagnosed with a carcinoma had a higher positive probability after treatment; one of those was re-diagnosed with carcinoma on the follow up visit. These results indicate that, although there were changes in the microbiota associated with treatment, those experienced by patients with carcinoma after treatment yielded gut bacterial communities of greater similarity to that of a normal colon.

***Difficult to identify effects of specific treatments on the change in the microbiota.***

The type of treatment that the patients received varied across diagnosis groups. Those with adenomas and advanced adenomas received surgical resection (adenoma, N=4; advanced adenoma, N=4) or polyp removal during colonoscopy (adenoma, N=18; advanced adenoma, N=15) and those with carcinomas received surgical resection (N=12), surgical resection with chemotherapy (N=9), and surgical resection with chemotherapy and radiation (N=5). We focused on the patients with carcinoma and pooled those patients that received chemotherapy with those that received chemotherapy and radiation to improve our statistical power. We did not observe a significant difference in the effect of these treatments on the number of observed OTUs, Shannon diversity, or Shannon evenness (P-value > 0.05). Furthermore, there was not a significant difference in the effect of the treatments on the amount of change in the community structure (P-value = 0.298). Finally, the change in the positive probability was not significantly different between the two treatment groups (P-value = 0.999). Due to the relatively small number of samples in



167 each treatment group, it was difficult to make a definitive statement regarding the specific  
168 type of treatment on the amount of change in the structure of the microbiota.

## Discussion

This study builds upon previous work that demonstrated a role for the microbiota in tumorigenesis and that microbiome-derived biomarkers can detect colonic lesions [6–10,24–28]. Our study focused on comparing the microbiota of patients diagnosed with adenoma, advanced adenoma, and carcinoma before and after treatment. For all three groups of patients, we observed changes in their microbiota. After treatment, the microbiota of patients with carcinoma changed significantly more than the other groups. This change resulted in communities that more closely resembled those of patients with a normal colon. This may suggest that treatment for carcinoma is not only successful for removing the carcinoma but also at reducing the associated bacterial communities. Understanding the effect of treatment on the microbiota of those diagnosed with carcinomas may have important implications for reducing disease recurrence. It is intriguing that it may be possible to use microbiome-based biomarkers to not only predict the presence of lesions but to assess the risk of recurrence.

Patients diagnosed with adenoma and advanced adenoma, however, did not experience a shift towards a community structure that resembled those with normal colons. This may be due to the fundamental differences between the features of adenomas and advanced adenomas and carcinoma. Specifically, carcinomas may create an inflammatory milieu that would impact the structure of the community and removal of that stimulus would alter said structure. In addition, it is possible that the difference between the microbiota of patients with adenoma and advanced adenoma and those with normal colons is subtle. This is supported by the reduced ability of our models to correctly classify patients with adenomas and advanced adenomas relative to those diagnosed with carcinomas [Figure S2]. Given the irregular distribution of microbiota across patients in the different diagnosis groups, it is possible that we lacked the statistical power to adequately characterize the change in the communities following treatment.

195 There was a subset of patients (6 of the 26 with carcinomas) who demonstrated an elevated  
196 probability of carcinoma after treatment. This may reflect an elevated risk of recurrence.  
197 The 23.08% prevalence of increased carcinoma probability from our study is within the  
198 expected rate of recurrence (20-30% [3,4]). We hypothesized that these individuals may  
199 have had more severe tumors; however, the tumor severity of these 6 individuals (3 with  
200 Stage II and 3 with Stage III) was similar to the distribution observed among the other 20  
201 patients. We also hypothesized that we may have sampled these patients later than the rest  
202 and their communities may have reverted to a carcinoma-associated state; however, there  
203 was not a statistically significant difference in the length of time between sample collection  
204 among those whose probabilities increased or decreased (Wilcoxon Test; P-value = 0.56).  
205 Finally, it is possible that these patients may not have responded to treatment as well as  
206 the other 20 patients diagnosed with carcinoma and so the microbiota may not have been  
207 impacted the same way. Again, further studies looking at the role of the microbiota in  
208 recurrence are needed to understand the dynamics following treatment.

209 Our final hypothesis was that the specific type of treatment altered the structure of  
210 the microbiome. The treatment to remove adenomas and advanced adenomas was  
211 either polyp removal or surgical resection whereas it was surgical resection alone or  
212 in combination with chemotherapy or with chemotherapy and radiation for individuals  
213 with carcinoma. Because chemotherapy and radiation target rapidly growing cells, these  
214 treatments would be more likely to cause a turnover of the colonic epithelium driving a  
215 more significant change in the structure of the microbiota. Although, we were able to  
216 test for an effect across these specific types of treatment, the number of patients in each  
217 treatment group was relatively small.

218 This study expands upon existing research that has established a role for the microbiota in  
219 tumorigenesis and that demonstrated the utility of microbiome-based biomarkers to predict  
220 the presence of colonic lesions. The most exciting future direction from the current study is

the possibility that markers within the microbiota could be used to evaluate the effect of treatment and predict recurrence for those diagnosed with carcinoma. If such an approach is effective, it might be possible to target the microbiota as part of adjuvant therapy. Our data provides additional evidence on the importance of the microbiota in tumorigenesis by addressing the recovery of the microbiota after treatment and opens interesting avenues of research into how these changes may affect recurrence.

## Methods

**Study Design and Patient Sampling.** Sampling and design have been previously reported in Baxter, et al [24]. Briefly, study exclusion involved those who had already undergone surgery, radiation, or chemotherapy, had colorectal cancer before a baseline fecal sample could be obtained, had IBD, a known hereditary non-polyposis colorectal cancer, or familial adenomatous polyposis. Samples used to build the models for prediction were collected either prior to a colonoscopy or between one and two weeks after initial colonoscopy. The bacterial community has been shown to normalize back to a pre-colonoscopy community within this time period [29]. Our study cohort consisted of 67 individuals with an initial sample as described and a follow up sample obtained between 188 - 546 days after treatment of lesion [Table 1]. Patients were diagnosed by colonoscopic examination and histopathological review of biopsies. Patients were classified as having advanced adenoma if they had an adenoma greater than 1 cm, more than three adenomas of any size, or an adenoma with villous histology. This study was approved by the University of Michigan Institutional Review Board. All study participants provided informed consent and the study itself conformed to the guidelines set out by the Helsinki Declaration.

**16S rRNA Gene Sequencing.** Sequencing was completed as described by Kozich, et al. [30]. DNA extraction used the 96-well Soil DNA isolation kit (MO BIO Laboratories) and an epMotion 5075 automated pipetting system (Eppendorf). The V4 variable region was amplified and the resulting product was split between three sequencing runs with normal, adenoma, and carcinoma evenly represented on each run. Each group was randomly assigned to avoid biases based on sample collection location. The pre and post-treatment samples were sequenced on the same run.

**Sequence Processing.** The mothur software package (v1.37.5) was used to process

the 16S rRNA gene sequences and has been previously described [30]. The general workflow using mothur included merging paired-end reads into contigs, filtering for low quality contigs, aligning to the SILVA database [31], screening for chimeras using UCHIME [32], classifying with a naive Bayesian classifier using the Ribosomal Database Project (RDP)[33], and clustered into Operational Taxonomic Units (OTUs) using a 97% similarity cutoff with an average neighbor clustering algorithm [34]. The number of sequences for each sample was rarefied to 10523 to minimize the impacts of uneven sampling.

**Model Building.** The Random Forest [35] algorithm was used to create the model used to create the three models used. The adenoma model classified normal versus adenoma, the advanced adenoma model classified normal versus advanced adenoma, and the carcinoma model classified normal versus carcinoma. The total number of individuals in the treatment models was 67 individuals. There were a total of 22 individuals in the treatment adenoma model, 19 individuals in the treatment advanced adenoma model, and 26 individuals in the treatment carcinoma model [Table 1]. The total number of individuals in the normal versus diagnosis models was 423 individuals [Table 2]. There were a total of 239 individuals in the adenoma model, 262 individuals in the advanced adenoma model, and 266 individuals in the carcinoma model [Table 2]. Each model was then applied to our 67-person cohort [Table 1] which assessed the prediction of pre-treatment adenoma (adenoma  $n = 22$ ) versus post-treatment adenoma (adenoma  $n = 0$ ), pre-treatment advanced adenoma (advanced adenoma  $n = 19$ ) versus post-treatment advanced adenoma (advanced adenoma  $n = 0$ ), pre-treatment carcinoma (carcinoma  $n = 26$ ) versus post-treatment carcinoma (carcinoma  $n = 1$ ).

The model included only OTU data obtained from 16S rRNA sequencing. Non-binary data was checked for near zero variance and OTUs that had near zero variance were removed. This pre-processing was performed with the R package caret (v6.0.73). Optimization of the mtry hyper-parameter involved making 100 different 80/20 (train/test) splits of the data

where normal and adenoma, normal and advanced adenoma, or normal and carcinoma were represented in the same proportion within both the whole data set and the 80/20 split. For each of the different splits, 20 repeated 10-fold cross validation was performed on the 80% component to optimize the mtry hyper-parameter by maximizing the AUC (Area Under the Curve of the Receiver Operator Characteristic). The resulting model was then tested on the hold out data obtained from the 20% component. All three models had an optimized mtry of 2. The hyper-parameter, mtry, defines the number of variables to investigate at each split before a new division of the data was created with the Random Forest model.

Assessment of the most important OTUs to the model involved counting the number of times an OTU was present in the top 10% of mean decrease in accuracy (MDA) for each of the 100 different splits run. This was then followed with filtering of this list to variables that were only present in more than 50% of these 100 runs. The final collated list of variables was then run through the mtry optimization again. Once the ideal mtry was found the entire sample set specific to normal versus adenoma, normal versus advanced adenoma, or normal versus carcinoma was used to create the final Random Forest model on which classifications on the 67-person cohort was completed. For all three models the final optimized mtry was 2. The only difference other than the sample set used between treatment models and normal versus diagnosis models was that only the top 10 OTUs were used to build each respective treatment model by diagnosis group to help avoid model overfitting.

**Statistical Analysis.** The R software package (v3.3.2) was used for all statistical analysis. Comparisons between bacterial community structure utilized PERMANOVA [36] in the vegan package (v2.4.1). Comparisons between probabilities as well as overall OTU differences between pre and post-treatment samples utilized a paired Wilcoxon ranked sum test. Where multiple comparison testing was appropriate, a Benjamini-Hochberg (BH) correction was applied [37] and a corrected P-value of less than 0.05 was considered

significant. Unless otherwise stated the P-values reported are those that were BH corrected. Model rank importance was determined by obtaining the median MDA from the 100, 20 repeated 10-fold cross validation and then ranking from largest to smallest MDA.

***Reproducible Methods.*** A detailed and reproducible description of how the data were processed and analyzed can be found at [https://github.com/SchlossLab/Size\\_followUps\\_2017](https://github.com/SchlossLab/Size_followUps_2017). Raw sequences have been deposited into the NCBI Sequence Read Archive (SRP062005 and SRP096978) and the necessary metadata can be found at <https://www.ncbi.nlm.nih.gov/Traces/study/> and searching the respective SRA study accession.



**Figure 1: General Differences between Adenoma, Advanced Adenoma, and Carcinoma Groups After Treatment.** A) A significant difference was found between the adenoma and carcinoma group for thetacy (P-value = 5.36e-05). Solid black points represent the median value for each diagnosis group. B) NMDS of the pre and post-treatment samples for the adenoma group. C) NMDS of the pre and post-treatment samples for the advanced adenoma group. D) NMDS of the pre and post-treatment samples for the carcinoma group.

**Figure 2: The 10 OTUs used to classify treatment for Adenoma, Advanced Adenoma, and Carcinoma.** A) Adenoma OTUs. B) Advanced Adenoma OTUs. C) Carcinoma OTUs.

**Figure 3: Treatment Response Based on Models Built for Adenoma, Advanced Adenoma, or Carcinoma.** A) Positive probability change from initial to follow up sample in those with adenoma. B) Positive probability change from initial to follow up sample in those with advanced adenoma. C) Positive probability change from initial to follow up sample in those with carcinoma.

**Figure 4: Common OTUs to All Models.** A) Venn diagram showing the OTU overlap between each model. B) For each common OTU the lowest taxonomic identification and importance rank for each model run is shown.

**Table 1: Demographic Data of pre and Post Treatment Cohort**

	Adenoma	Advanced Adenoma	Carcinoma
n	22	19	26
Age (Mean $\pm$ SD)	61.68 $\pm$ 7.2	63.11 $\pm$ 10.9	61.65 $\pm$ 12.9
Sex (%F)	36.36	36.84	42.31
BMI (Mean $\pm$ SD)	26.86 $\pm$ 3.9	25.80 $\pm$ 4.7	28.63 $\pm$ 7.2
Caucasian (%)	95.45	84.21	96.15

**Table 2: Demographic Data of Training Cohort**

	Normal	Adenoma	Advanced Adenoma	Carcinoma
n	172	67	90	94
Age (Mean $\pm$ SD)	54.29 $\pm$ 9.9	63.01 $\pm$ 13.1	64.07 $\pm$ 11.3	64.37 $\pm$ 12.9
Sex (%F)	64.53	46.27	37.78	43.62
BMI (Mean $\pm$ SD)	26.96 $\pm$ 5.3	25.68 $\pm$ 4.8	26.66 $\pm$ 4.9	29.27 $\pm$ 6.7
Caucasian (%)	87.79	92.54	92.22	94.68

**Figure S1: Distribution of P-values from Paired Wilcoxon Analysis of All OTUs Before and After Treatment**

**Figure S2: ROC Curves of the Adenoma, Advanced Adenoma, and Carcinoma**

**Models.** A) Adenoma ROC curve: The light green shaded areas represent the range of values of a 100 different 80/20 splits of the test set data and the dark green line represents the model using 100% of the data set and what was used for subsequent classification. B) Advanced Adenoma ROC curve: The light yellow shaded areas represent the range of values of a 100 different 80/20 splits of the test set data and the dark yellow line represents the model using 100% of the data set and what was used for subsequent classification. C) Carcinoma ROC curve: The light red shaded areas represent the range of values of a 100 different 80/20 splits of the test set data and the dark red line represents the model using 100% of the data set and what was used for subsequent classification.

**Figure S3: Summary of Important OTUs for the Adenoma, Advanced Adenoma, and**

**Carcinoma Models.** A) MDA of the most important variables in the adenoma model. The dark green point represents the mean and the lighter green points are the value of each of the 100 different runs. B) Summary of Important Variables in the advanced adenoma model. MDA of the most important variables in the SRN model. The dark yellow point represents the mean and the lighter yellow points are the value of each of the 100 different runs. C) MDA of the most important variables in the carcinoma model. The dark red point represents the mean and the lighter red points are the value of each of the 100 different runs.

## **Declarations**

### **Ethics approval and consent to participate**

The University of Michigan Institutional Review Board approved this study, and all subjects provided informed consent. This study conformed to the guidelines of the Helsinki Declaration.

### **Consent for publication**

Not applicable.

### **Availability of data and material**

A detailed and reproducible description of how the data were processed and analyzed can be found at [https://github.com/SchlossLab/Size\\_followUps\\_2017](https://github.com/SchlossLab/Size_followUps_2017). Raw sequences have been deposited into the NCBI Sequence Read Archive (SRP062005 and SRP096978) and the necessary metadata can be found at <https://www.ncbi.nlm.nih.gov/Traces/study/> and searching the respective SRA study accession.

### **Competing Interests**

All authors declare that they do not have any relevant competing interests to report.

## **Funding**

This study was supported by funding from the National Institutes of Health to P. Schloss (R01GM099514, P30DK034933) and to the Early Detection Research Network (U01CA86400).

## **Authors' contributions**

All authors were involved in the conception and design of the study. MAS analyzed the data. NTB processed samples and analyzed the data. All authors interpreted the data. MAS and PDS wrote the manuscript. All authors reviewed and revised the manuscript. All authors read and approved the final manuscript.

## **Acknowledgements**

The authors thank the Great Lakes-New England Early Detection Research Network for providing the fecal samples that were used in this study. We would also like to thank Amanda Elmore for reviewing and correcting code error and providing feedback on manuscript drafts. We would also like to thank Nicholas Lesniak for providing feedback on manuscript drafts.

## References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. *CA: a cancer journal for clinicians*. 2016;66:7–30.
2. Haggard FA, Boushey RP. Colorectal cancer epidemiology: Incidence, mortality, survival, and risk factors. *Clinics in Colon and Rectal Surgery*. 2009;22:191–7.
3. Hellinger MD, Santiago CA. Reoperation for recurrent colorectal cancer. *Clinics in Colon and Rectal Surgery*. 2006;19:228–36.
4. Ryuk JP, Choi G-S, Park JS, Kim HJ, Park SY, Yoon GS, et al. Predictive factors and the prognosis of recurrence of colorectal cancer within 2 years after curative resection. *Annals of Surgical Treatment and Research*. 2014;86:143–51.
5. Institute NC. SEER Cancer Stat Facts: Colon and Rectum Cancer [Internet]. [cited 2017 Apr 27]. Available from: <http://seer.cancer.gov/statfacts/html/colorect.html>
6. Goodwin AC, Destefano Shields CE, Wu S, Huso DL, Wu X, Murray-Stewart TR, et al. Polyamine catabolism contributes to enterotoxigenic *Bacteroides fragilis*-induced colon tumorigenesis. *Proceedings of the National Academy of Sciences of the United States of America*. 2011;108:15354–9.
7. Abed J, Emgård JEM, Zamir G, Faroja M, Almogy G, Grenov A, et al. Fap2 Mediates *Fusobacterium nucleatum* Colorectal Adenocarcinoma Enrichment by Binding to Tumor-Expressed Gal-GalNAc. *Cell Host & Microbe*. 2016;20:215–25.
8. Arthur JC, Gharaibeh RZ, Mühlbauer M, Perez-Chanona E, Uronis JM, McCafferty J, et al. Microbial genomic analysis reveals the essential role of inflammation in bacteria-induced

colorectal cancer. *Nature Communications*. 2014;5:4724.

9. Kostic AD, Chun E, Robertson L, Glickman JN, Gallini CA, Michaud M, et al. *Fusobacterium nucleatum* potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. *Cell Host & Microbe*. 2013;14:207–15.

10. Wu S, Rhee K-J, Albesiano E, Rabizadeh S, Wu X, Yen H-R, et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. *Nature Medicine*. 2009;15:1016–22.

11. Zackular JP, Baxter NT, Chen GY, Schloss PD. Manipulation of the Gut Microbiota Reveals Role in Colon Tumorigenesis. *mSphere*. 2016;1.

12. Zackular JP, Baxter NT, Iverson KD, Sadler WD, Petrosino JF, Chen GY, et al. The gut microbiome modulates colon tumorigenesis. *mBio*. 2013;4:e00692–00613.

13. Baxter NT, Zackular JP, Chen GY, Schloss PD. Structure of the gut microbiome following colonization with human feces determines colonic tumor burden. *Microbiome*. 2014;2:20.

14. Flynn KJ, Baxter NT, Schloss PD. Metabolic and Community Synergy of Oral Bacteria in Colorectal Cancer. *mSphere*. 2016;1.

15. Wang T, Cai G, Qiu Y, Fei N, Zhang M, Pang X, et al. Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers. *The ISME journal*. 2012;6:320–9.

16. Chen H-M, Yu Y-N, Wang J-L, Lin Y-W, Kong X, Yang C-Q, et al. Decreased dietary fiber intake and structural alteration of gut microbiota in patients with advanced colorectal adenoma. *The American Journal of Clinical Nutrition*. 2013;97:1044–52.

17. Chen W, Liu F, Ling Z, Tong X, Xiang C. Human intestinal lumen and mucosa-associated



- 426 microbiota in patients with colorectal cancer. *PloS One*. 2012;7:e39743.
- 427 18. Shen XJ, Rawls JF, Randall T, Burcal L, Mpande CN, Jenkins N, et al. Molecular  
428 characterization of mucosal adherent bacteria and associations with colorectal adenomas.  
429 *Gut Microbes*. 2010;1:138–47.
- 430 19. Kostic AD, Gevers D, Pedamallu CS, Michaud M, Duke F, Earl AM, et al. Genomic  
431 analysis identifies association of *Fusobacterium* with colorectal carcinoma. *Genome*  
432 *Research*. 2012;22:292–8.
- 433 20. Feng Q, Liang S, Jia H, Stadlmayr A, Tang L, Lan Z, et al. Gut microbiome  
434 development along the colorectal adenoma-carcinoma sequence. *Nature Communications*.  
435 2015;6:6528.
- 436 21. Dejea CM, Wick EC, Hechenbleikner EM, White JR, Mark Welch JL, Rossetti BJ, et al.  
437 Microbiota organization is a distinct feature of proximal colorectal cancers. *Proceedings of*  
438 *the National Academy of Sciences of the United States of America*. 2014;111:18321–6.
- 439 22. Mima K, Sukawa Y, Nishihara R, Qian ZR, Yamauchi M, Inamura K, et al.  
440 *Fusobacterium nucleatum* and T Cells in Colorectal Carcinoma. *JAMA oncology*.  
441 2015;1:653–61.
- 442 23. Arthur JC, Perez-Chanona E, Mühlbauer M, Tomkovich S, Uronis JM, Fan T-J, et al.  
443 Intestinal inflammation targets cancer-inducing activity of the microbiota. *Science (New*  
444 *York, N.Y.)*. 2012;338:120–3.
- 445 24. Baxter NT, Ruffin MT, Rogers MAM, Schloss PD. Microbiota-based model improves the  
446 sensitivity of fecal immunochemical test for detecting colonic lesions. *Genome Medicine*.  
447 2016;8:37.
- 448 25. Zeller G, Tap J, Voigt AY, Sunagawa S, Kultima JR, Costea PI, et al. Potential of

fecal microbiota for early-stage detection of colorectal cancer. *Molecular Systems Biology*. 2014;10:766.

26. Zackular JP, Rogers MAM, Ruffin MT, Schloss PD. The human gut microbiome as a screening tool for colorectal cancer. *Cancer Prevention Research (Philadelphia, Pa.)*. 2014;7:1112–21.

27. Yu J, Feng Q, Wong SH, Zhang D, Liang QY, Qin Y, et al. Metagenomic analysis of faecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer. *Gut*. 2017;66:70–8.

28. Warren RL, Freeman DJ, Pleasance S, Watson P, Moore RA, Cochrane K, et al. Co-occurrence of anaerobic bacteria in colorectal carcinomas. *Microbiome*. 2013;1:16.

29. O'Brien CL, Allison GE, Grimpen F, Pavli P. Impact of colonoscopy bowel preparation on intestinal microbiota. *PloS One*. 2013;8:e62815.

30. Kozich JJ, Westcott SL, Baxter NT, Highlander SK, Schloss PD. Development of a dual-index sequencing strategy and curation pipeline for analyzing amplicon sequence data on the MiSeq Illumina sequencing platform. *Applied and Environmental Microbiology*. 2013;79:5112–20.

31. Pruesse E, Quast C, Knittel K, Fuchs BM, Ludwig W, Peplies J, et al. SILVA: A comprehensive online resource for quality checked and aligned ribosomal RNA sequence data compatible with ARB. *Nucleic Acids Research*. 2007;35:7188–96.

32. Edgar RC, Haas BJ, Clemente JC, Quince C, Knight R. UCHIME improves sensitivity and speed of chimera detection. *Bioinformatics (Oxford, England)*. 2011;27:2194–200.

33. Wang Q, Garrity GM, Tiedje JM, Cole JR. Naive Bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy. *Applied and*

- 472 Environmental Microbiology. 2007;73:5261–7.
- 473 34. Schloss PD, Westcott SL. Assessing and improving methods used in operational  
474 taxonomic unit-based approaches for 16S rRNA gene sequence analysis. Applied and  
475 Environmental Microbiology. 2011;77:3219–26.
- 476 35. Breiman L. Random Forests. Machine Learning [Internet]. 2001 [cited 2013 Feb  
477 7];45:5–32. Available from: <http://link.springer.com/article/10.1023/A%3A1010933404324>  
478 <http://link.springer.com/article/10.1023%2FA%3A1010933404324?LI=true>
- 479 36. Anderson MJ, Walsh DCI. PERMANOVA, ANOSIM, and the Mantel test in the face of  
480 heterogeneous dispersions: What null hypothesis are you testing? Ecological Monographs  
481 [Internet]. 2013 [cited 2017 Jan 5];83:557–74. Available from: [http://doi.wiley.com/10.1890/](http://doi.wiley.com/10.1890/12-2010.1)  
482 12-2010.1
- 483 37. Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and  
484 powerful approach to multiple testing. Journal of the Royal Statistical Society. Series B  
485 (Methodological). 1995;57:289–300.